Eosinophilic rash secondary to temsirolimus

Area of Science:

• Oncology
• Dermatology
• Pharmacology

Background:

• Metastatic renal cell carcinoma (mRCC) treatment often involves targeted therapies like temsirolimus.
• Temsirolimus, a mammalian target of rapamycin (mTOR) inhibitor, offers survival benefits but can cause dermatologic toxicities.
• Early recognition and management of these toxicities are crucial for patient quality of life and treatment adherence.

Observation:

• A 73-year-old female with mRCC developed a pruritic rash on her antecubital areas and posterior knees.
• The rash appeared after two weeks of weekly temsirolimus infusions.
• Skin biopsy revealed spongiotic dermatitis with eosinophils, indicative of a drug reaction.

Findings:

• The patient's rash was diagnosed as a drug eruption secondary to temsirolimus.
• Topical clobetasol was initiated for treatment.
• The rash resolved completely within two weeks of topical clobetasol application.

Implications:

• Dermatologic side effects of mTOR inhibitors like temsirolimus require prompt identification and management.
• Effective management of skin toxicities can prevent treatment discontinuation and maintain patient quality of life.
• Further research into the mechanisms of temsirolimus-induced skin toxicity may lead to improved supportive care strategies.